Christophe Weber

Shire Accepts Improved $62B Bid From Takeda
Strategy

Shire Accepts Improved $62B Bid From Takeda

The deal is the largest-ever by a Japanese company and gives Takeda a lucrative portfolio of rare disease drugs.
By Matthew Heller | May 8, 2018
Read More
Takeda Buys Ariad in $5.2B Cancer Drug Bet
Strategy

Takeda Buys Ariad in $5.2B Cancer Drug Bet

The Japanese drug giant is paying a 75% premium for Ariad to "transform our global solid tumor franchise."
By Matthew Heller | January 10, 2017
Read More